WithdrawnPhase 2NCT05116800

Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma

Studying Angiosarcoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Brown University
Principal Investigator
Bradley D DeNardo, MD, MD
Brown University
Intervention
Gemcitabine(drug)
Eligibility
10 years · All sexes
Timeline
2022 – 2030

Study locations (2)

Collaborators

Actuate Therapeutics Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05116800 on ClinicalTrials.gov

Other trials for Angiosarcoma

Additional recruiting or active studies for the same condition.

See all trials for Angiosarcoma →

← Back to all trials